ABSTRACT
Objective To understand the relationship across the glycaemic spectrum, with brain health. We hypothesised that individuals with increasingly higher HbA1c would be more likely to have worse brain health outcomes in comparison to normoglycaemic individuals.
Methods UK Biobank participants. HbA1c and diabetes diagnosis define baseline glycaemic categories. Outcomes: incident vascular dementia (VD), Alzheimer’s dementia (AD), hippocampal volume (HV), white matter hyperintensity (WMH) volume, cognitive function and decline. Reference group: normoglycaemic individuals (HbA1c 35-<42 mmol/mol).
Results Pre- and known diabetes increased incident VD, (HR 1.54, 95%CI=1.04;2.28 and 2.97, 95%CI=2.26;3.90). Known diabetes increased AD risk (HR 1.84, 95%CI=1.44;2.36). Pre- and known diabetes elevated risks of cognitive decline (OR 1.42, 1.48;2.96 and 1.39, 1.04;1.75). Pre-diabetes, undiagnosed and known diabetes conferred higher WMH volumes (4%, 26%, 5%,) and lower HV (22.4mm3, 15.2mm3, 62.2mm3). Low-normal HbA1c had 2% lower WMH volume and 13.6mm3 greater HV.
Interpretation Pre and known diabetes increase VD risks; known diabetes increases AD risk. Low-normal HbA1c associates with more favourable neuroimaging outcomes. Our findings may have implications for cardiovascular medication in hyperglycaemia for brain health.
Competing Interest Statement
Author contributions: literature search: VG; study design: VG, NC; data analysis: VG, SVE, A-EF; data interpretation: VG, NC, LS, KB; Writing: VG, NC; commenting on the draft: VG, A-EF, SVE, RM, CTR, KB, LS, NC. KB reports grants from Diabetes UK, grants from British Heart Foundation, during the conduct of the study; grants from Medical Research Council, outside the submitted work. KB holds a Sir Henry Dale Fellowship funded by Wellcome and the Royal Society (grant number 107731/Z/15/Z). LS reports grants from BHF and Diabetes UK, during the conduct of the study; grants from Wellcome, grants from MRC, grants from NIHR, grants from GSK, grants from BHF, outside the submitted work; and is a Trustee of the British Heart Foundation. NC reports grants from Diabetes UK, grants from British Heart Foundation, during the conduct of the study; personal fees from AstraZeneca, grants from Medical Research Council, outside the submitted work. The remaining authors declare that there are no conflicts of interest.
Funding Statement
This work was jointly funded by Diabetes UK and British Heart Foundation grant 15/0005250.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data to support this study are available directly from UK Biobank.
